This is an Accepted Manuscript, which has been through the Royal Society of Chemistry peer review process and has been accepted for publication.

Accepted Manuscripts are published online shortly after acceptance, before technical editing, formatting and proof reading. Using this free service, authors can make their results available to the community, in citable form, before we publish the edited article. We will replace this Accepted Manuscript with the edited and formatted Advance Article as soon as it is available.

You can find more information about Accepted Manuscripts in the Information for Authors.

Please note that technical editing may introduce minor changes to the text and/or graphics, which may alter content. The journal’s standard Terms & Conditions and the Ethical guidelines still apply. In no event shall the Royal Society of Chemistry be held responsible for any errors or omissions in this Accepted Manuscript or any consequences arising from the use of any information it contains.
First total synthesis of ganglioside DSG-A possessing neuritogenic activity

Yu-Fa Wu,a Yow-Fu Tsai,*a Jhe-Ruei Guo,a Cheng-Ping Yu,a Hui-Ming Yu,*b and Chun-Chen Liaoa

Received 00th January 2012, Accepted 00th January 2012
DOI: 10.1039/x0xx00000x

www.rsc.org/

The first total synthesis of ganglioside DSG-A (1) has been achieved via chemoselective glycosylation and a [1+1+2] synthetic strategy. We have also developed an efficient method that can be handled in large scale (50 g) for the synthesis of the phytosphingosine.

Gangliosides, sialic acid-containing glycosphingolipids, are most abundant in the brain and nervous system where they comprise up to 6% of the total lipids. However, they are also ubiquitous in other tissues. Many studies have indicated that gangliosides play a pivotal role not only in cell-cell and cell-matrix interactions, but also in the development and the functions of the nervous system. For example, mice lacking complex gangliosides, such as GD1α and GT1b, display progressive symptoms similar to those of axon degeneration and gross dysmyelination seen in neurodegenerative diseases. Furthermore, numerous studies have demonstrated that administration of ganglioside GM1 to patients with Parkinson’s disease or a number of different types of central nervous system lesion results in significant symptom reduction, as well as biochemical and behavioral recovery. These results suggest that gangliosides may serve as potential candidates for treating neurodegenerative diseases.

Many gangliosides extracted from marine invertebrates show neuritogenic activity against the rat pheochromocytoma cell line PC-12 in the presence of NGF. Among these gangliosides, SJG-2, LLG-3, GAA-7, LLG-5 and DSG-A (1) were found to be more effective than the mammalian ganglioside GM1, suggesting that these echinodermatous gangliosides can be considered as lead compounds for the development of chemotherapeutic agents for the treatment of neurodegenerative diseases. DSG-A, isolated from the ovary of the sea urchin Diadema setosum, has a simpler structure, (9-O-Me-Neu5Acα(2→6)Glcβ(1→1)Cer possessing a 2-hydroxy octadecanoyl moiety), than the other gangliosides. However, to-date, DSG-A has not yet been synthesized and its mechanism of stimulating neurogenesis remains unclear because of the difficulty in obtaining a sufficient amount and purity of it from natural resources. Thus it is important to develop a powerful synthetic strategy for getting sufficient DSG-A, not only for efficacious validation but also for further structural modifications to examine the structure-activity relationships (SAR). Herein, we wish to report a total synthesis of DSG-A with an efficient methodology for a gram-scale (50 g) synthesis of the phytosphingosine moiety.

The retrosynthetic analysis of DSG-A (1) is outlined in Scheme 1. We intend adopting a [1+1+2] strategy to assemble the four building blocks, including the sialyl donor 4 or 5, the glucose derivative 6, the succinimidy acetoxyester 7, and the phytosphingosine derivative 8. The glucosyl acceptor 6 was first sialylated with sialyl donor 4 or 5 to give the disaccharide 2a which was then glycosylated with the phytoceramide 3, readily prepared by the amidization of amine 8 with the succinimidyl ester 7, to generate the target molecule DSG-A. It is noteworthy that in order to achieve highly chemoselective glycosylations, the BoxS and EtS groups were introduced at the anomeric carbons of 4 (or 5) and 6, respectively. For the β-stereoselective glycosylation of disaccharide 2 with phytoceramide 3, a group displaying a neighboring group effect to control the stereoselectivity was added to the C2-OH of glucose 6. Moreover, to enhance the reactivity of glycosylation electron-donating groups were added to the C3- and C4-OH in 6.

The preparative methods used to obtain 4 and 5 are shown in Scheme 2. Peracetyl phenylthioglycoside was first deacylated with MeONa/MeOH to give tetrac 10, which was used without further purification for the chemoselective methylation on C9-OH with Meerwein reagent in MeCN in the presence of DTBMP at -10 °C to generate monomethylated 11 in 82% yield over two steps. To avoid affecting the subsequent conversion of the PhS group in compound 11 to BoxS, the free hydroxyl group of triol 11 was protected with Ac2O/pyridine at room temperature to produce the acetate 12 in 95% yield. The PhS group was then converted into the BoxS group by chlorination of 12 with iodine chloride, followed by
substitution of the resulting chloride with 2-mercaptobenzoxazole (HSBox) in the presence of Hunig’s base.20 The desired sialyl donor was obtained in 70% overall yield in two steps. For the synthesis of the sialyl donor 5, the oxazolidinone 13 was synthesized using a documented protocol.11 The subsequent procedure for the methylation of C9-OH in 13 and conversion of the PhS group in compound 14 to BoxS was the same as that of the conversion of compound 11 to compound 4.

After preparing the desired sialyl donors 4 and 5, we then focused on the synthesis of a suitable glucose derivative such as 6 that could function as both glycosyl acceptor and donor (Scheme 3). The commercially available pentaacetylated glucose 15, which was employed as a starting material, was transformed into the orthoester 16 by a known method.12 To simplify the reaction procedures, we developed a one-pot thioethylation and desilylation of orthoester 16 by treatment with EtSH in the presence of HgBr2 at 60 °C followed by saturation of the double bond and removal of the TBS group; the desilylation occurred presumably due to the presence of trace acid and water. The hydroxyl group in 23 was protected with Ac2O/pyridine to form the acetate followed by esterification with N-hydroxysuccinimide to provide the desired succinimidyl acetoxyester 7 in 86% yield in two steps. The preparations of the phytosphingosine derivative 8 and phytoceramide 3 are illustrated in Scheme 5. The primary hydroxyl group of substrate 2413 was first chemoselectively silylated with TIPSICl, and the resulted silyl ether 25 gave enol 26 by Wittig olefination in 73% overall yield in two steps. Enol 26 was converted to mesylate 27 (97% yield), which was then desilylated with TBAF to afford the hydroxymesylate 28 in 96% yield. To introduce the required amino group at C-2 in phytosphingosine, tandem addition and intramolecular cyclization of hydroxymesylate 28 with benzylisocyanate in the presence of NaOH was employed to generate the 2-oxazolidone 29 in 81% yield,14 which was then subjected to a cross-metathesis reaction with 1-tetradecene in the presence of Grubbs’ catalyst to form phytosphingosine derivative 30 as a 16:1 mixture of E- and Z-stereoisomers in 94% yield.15 Upon exposure to NaOH in MeOH-H2O, oxazolidone 30 was converted to the benzylammonium 31 in 94% yield. Hydrogenation of 31 followed by amidization of the corresponding aminooctanol 8 (99%) with succinimidyl acetoxyester 7 generated the required phosphoceramide 3 in 94% yield.

Before completing the synthesis of ganglioside DSG-A, glycosylation of the sialyl donors with a glucosyl acceptor was first evaluated (Table 1). The best result was obtained by glycosylating donor 5 with acceptor 6, which was carried out in the presence of thiocarbonil 19 with EtSH in the presence of EDC/DMAP in dry CH2Cl2. The desired glucosylated product 20 was obtained in 93% yield, which was then transformed into aldehyde 21 with Fukuyama’s method in 91% yield. To establish the long-carbon side chain, Wittig olefination was carried out using aldehyde 21 as a substrate to generate the protected hydroxyalkenone 22 in 82% yield as a single (E)-stereoisomer, fully characterized by its 1H NMR spectrum (δ Double bond H) 5.47 (d, J = 15.6 Hz). Treatment of 22 with H2/10% Pd/C produced hydroxyalkanolic acid 23 as a white solid in 91% yield ([α]D +16.6 (c 0.10, MeOH)) by debenzylation, saturation of the double bond and removal of the TBS group; the desilylation occurred presumably due to the presence of trace acid and water. The hydroxyl group in 23 was protected with Ac2O/pyridine to form the acetate followed by esterification with N-hydroxysuccinimide to provide the desired succinimidyl acetoxyester 7 in 86% yield in two steps. The preparations of the phytosphingosine derivative 8 and phytoceramide 3 are illustrated in Scheme 5. The primary hydroxyl group of substrate 2413 was first chemoselectively silylated with TIPSICl, and the resulted silyl ether 25 gave enol 26 by Wittig olefination in 73% overall yield in two steps. Enol 26 was converted to mesylate 27 (97% yield), which was then desilylated with TBAF to afford the hydroxymesylate 28 in 96% yield. To introduce the required amino group at C-2 in phytosphingosine, tandem addition and intramolecular cyclization of hydroxymesylate 28 with benzylisocyanate in the presence of NaOH was employed to generate the 2-oxazolidone 29 in 81% yield,14 which was then subjected to a cross-metathesis reaction with 1-tetradecene in the presence of Grubbs’ catalyst to form phytosphingosine derivative 30 as a 16:1 mixture of E- and Z-stereoisomers in 94% yield.15 Upon exposure to NaOH in MeOH-H2O, oxazolidone 30 was converted to the benzylammonium 31 in 94% yield. Hydrogenation of 31 followed by amidization of the corresponding aminooctanol 8 (99%) with succinimidyl acetoxyester 7 generated the required phosphoceramide 3 in 94% yield.

Before completing the synthesis of ganglioside DSG-A, glycosylation of the sialyl donors with a glucosyl acceptor was first evaluated (Table 1). The best result was obtained by glycosylating donor 5 with acceptor 6, which was carried out in the presence of
activator AgOTf in CH₂Cl₂ to give disaccharide 32α as a single α-stereoisomer in excellent yield (93%) (entry 8). To glycosylate the

donor 4 with the acceptor 6, eight sets of reaction conditions (promoter, solvent, and temperature) were used to generate glycal 33 and the disaccharide 2 as a mixture of the α- and β-stereoisomers; among of the tested conditions, only that in entry 5 resulted in a good yield and stereoselectivity for disaccharide 2. For example, in Et₂O and in CPME (promoter AgOTf), the yields of the disaccharide were 54% or 46%, respectively, and the β-stereoisomer was the major product (entries 1 and 3). Although activation by Cu(OTf)₂ in THF resulted in a greater stereoselectivity (α:β = 8:1), the yield of the desired disaccharide was very poor (entry 7, 29%).

Next, we turned our attention to the coupling of the disaccharide 2α with the protected phytoceramide 3. As shown in Scheme 6, excellent stereoselectivity (β only) and a higher yield (82%) for the synthesis of the protected DSG-A analogue 34 were achieved by the use of NIS/AgOTf in CH₂Cl₂ at -70 °C. In contrast, activator MeOTf reduced the yield dramatically (55%) though excellent stereoselectivity (β only) was maintained.

Finally, the target molecule DSG-A was accomplished as shown in Scheme 7. The disaccharide 32α was first converted into 2α in 82% yield by a three-step sequence, involving amidization, deacetylation, decarboxylation and acetylation. The protected phytoceramide 3 was glycosylated with 2α in the presence of the promoter NIS/AgOTf in anhydrous CH₂Cl₂ at -70 °C to generate the protected DSG-A analogue 34 in 82% yield with the glucose moiety in β-configuration, as demonstrated with its ¹H NMR spectrum (δ_α(1H) 4.31 (d, J = 8.0 Hz). Deisopropylideneation was then performed by treatment of 34 with 80% AcOH at 85 °C to give the diol 35 in 90% yield. Debenzylation of 35 using H₂/20% Pd(OH)₂ followed by deacetylation generated DSG-A (1) as a white solid compound in 96% yield in two steps.

Conclusions

In summary, we have achieved the first total synthesis of ganglioside DSG-A by employing a [1+1+2] synthetic strategy and chemoselective glycosylation. The glycosylation of sialyl donor 5 with glucosyl acceptor 6 and the conjugation of the synthesized disaccharide 2α with the protected phytoceramide 3 both resulted in excellent yield and stereoselectivity. In addition, we have also developed an...
efficient method that can be applied to a large scale synthesis of phytosphingosine (50 g) in an efficient manner. Currently,

the application of one-pot two-step glycosylations to prepare a variety of DSG-A analogues for various biological tests, including neuritogenic activity, is under active investigation.

Acknowledgements

We gratefully acknowledge financial support from the Ministry of Science and Technology, Taiwan (NSC 102-2113-M-033-003, NSC 102-2113-M-033-007, and NSC 101-2120-M-033-001).

Notes and references